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Crizotinib was approved for the treatment of advanced non–small-cell lung cancer patients with ALK fusion 
as detected by the ALK fluorescence in situ hybridization 
(FISH) test. The assay clearly defined that isolated 5′ ALK 
signals are considered ALK negative because the 5′ probe is 
not located in the kinase region. However, here, we describe 
a case with a negative FISH result that was later identified 
as ALK+ by VENTANA ALK (D5F3) immunohistochemisty 
(IHC) and responded well to crizotinib. Targeted next genera-
tion sequencing revealed a new ALK partner gene, baculoviral 
inhibition of apoptosis protein repeat containing six (BIRC6), 
and the paracentric inversion for generating this fusion gene.
CASE PRESENTATION
A 45-year-old Chinese woman with an 8 pack-year smoking 
history was referred to Cancer Hospital, Chinese Academy 
of Medical Sciences in February 2014 for bilateral pleural 
and pericardial effusion. Computed tomography of the chest 
revealed a left hilar mass, measured 3.1 × 3.4 cm2, and multiple 
enlarged lymph nodes in the right lymph node stations 1, 2R, 
4R, and 6. An incision biopsy of lymph nodes revealed a meta-
static adenocarcinoma. Molecular pathologic analysis showed 
no EGFR or KRAS mutations. FISH analysis revealed a nega-
tive result: over 50% of cancer cells demonstrated isolated 5′ 
ALK signals (green) and 2 copies of fused 5′ and 3′ ALK sig-
nals (Fig. 1B). However, IHC assay demonstrated strong ALK 
expression (Fig. 1A). Biotinylated oligoprobes were designed 
tiling along the nonrepeated regions of ALK gene containing 
all the exons and introns to capture fragmented ALK gene. The 
captured DNA was then sequenced on HiSeq 2000 sequencer 
(Illumina, San Diego, CA) for paired 100 bp read. The next 
generation sequence analysis revealed a new ALK partner gene, 
BIRC6, located at 2.4 Mb downstream of ALK. Direct Sanger 
sequencing demonstrated that intron 10 of BIRC6 is disrupted 
at a point, 7.2 kb downstream of exon 10, and is inverted to con-
nect to a position 411 bp upstream of exon 20 of ALK (Fig. 2A).
BIRC6 is a member of inhibitors of apoptosis proteins. In 
the predicted fusion protein, the N-terminal portion of BIRC6 
is fused to the intracellular region of ALK containing the trans-
membrane domain and tyrosine kinase domain, which is the 
binding site for crizotinib (Fig. 2B). Given the evidence that 
strong ALK expression was detected by IHC assay, the patient 
received crizotinib orally at a dose of 250 mg twice daily in 
March 2014 with an impressive symptomatic improvement 
and computed tomography response after 1 month of therapy 
(Fig. 1C–G). The patient remains on treatment with crizotinib 
with no evidence of progression as of November 2014.
DISCUSSION
This is the first report of a novel BIRC6-ALK fusion gene in 
non– small-cell lung cancer. According to FISH interpretation 
criteria, isolated 5′ ALK signals are considered ALK negative. 
In this case, given the short distance (~3 Mb) between 2 break-
points in ALK and BIRC6, the inversion may not be revealed by 
breaking-apart signals. However, it is still difficult to explain 
the multiple single copies of 5′ ALK signals. It indicated that 
there is not a simple inversion but a possibility of a complex 
rearrangement.1 Isolated 5′ ALK signals have been previously 
reported regardless whether EML4 was still the fusion part-
ner, and patients whose tumors harbored this type of signals 
responded well to crizotinib.2–4 Therefore ALK FISH negative 
criteria are challenged. If FISH is the initial diagnosis in clinical 
practice, isolated 5′ ALK signals should raise the pathologists’ 
notice to apply the alternative confirmatory assays, ideally IHC 
assay, to confirm the ALK fusion status.
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FIGURE 1. A. VENTANA ALK (D5F3) IHC assay revealed intense granular cytoplasmic staining in this case. Original magnification 
×200. B, Specimen hybridized with the Vysis break-apart ALK FISH assay showing multiple single 5′ ALK signals (green) with two 
copies of fused 5′ and 3′ ALK signals (white arrows and a box). C, E, CT scan of mediastinal lymph nodes and thorax before initiation 
of crizotinib. D, F, CT scan of mediastinal lymph nodes and thorax after 1 month therapy of crizotinib. G, CT scan of thorax after 
3-month therapy of crizotinib. IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; CT, computed tomography.
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FIGURE 2. A, Both the ALK gene and the BIRC6 gene map to 
chromosome 2p, but have opposite orientations. BIRC6 located 
at 2.4 Mb downstream of ALK and 9.5 Mb upstream of EML4. 
Direct Sanger sequencing in this case showed that BIRC6 is 
disrupted at a position, 7.2 kb downstream of exon 10 and is 
inverted to connect to a position 411 bp upstream of exon 20 
of ALK. Given the short distance (~3 Mb) between 2 breakpoints 
in ALK and BIRC6, the inversion was not revealed by breaking-
apart signals in FISH analysis. B, Fusion of the N-terminal 
portion of BIRC6 (comprising BIR and UBCc domain) to the 
intracellular region of ALK (containing the TM and tyrosine 
kinase domain). BIR, a baculoviral inhibition of apoptosis pro-
tein repeat domain; UBCc, a ubiquitin-conjugating enzyme E2, 
catalytic domain; TM, transmembrane domain.
